These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 24246087

  • 21. The Burden of Obesity in Type 1 Diabetic Subjects: A Sex-specific Analysis From the AMD Annals Initiative.
    Giandalia A, Russo GT, Ruggeri P, Giancaterini A, Brun E, Cristofaro M, Bogazzi A, Rossi MC, Lucisano G, Rocca A, Manicardi V, Bartolo PD, Cianni GD, Giuliani C, Napoli A.
    J Clin Endocrinol Metab; 2023 Oct 18; 108(11):e1224-e1235. PubMed ID: 37247381
    [Abstract] [Full Text] [Related]

  • 22. Effect of a chronic disease management service for patients with diabetes on hospitalisation and acute care costs.
    Rasekaba TM, Lim WK, Hutchinson AF.
    Aust Health Rev; 2012 May 18; 36(2):205-12. PubMed ID: 22624643
    [Abstract] [Full Text] [Related]

  • 23. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia.
    Haji Ali Afzali H, Gray J, Beilby J, Holton C, Karnon J.
    Appl Health Econ Health Policy; 2013 Dec 18; 11(6):661-70. PubMed ID: 24243516
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH, Aagren M, Valentine WJ.
    J Med Econ; 2009 Jun 18; 12(2):114-23. PubMed ID: 19545216
    [Abstract] [Full Text] [Related]

  • 25. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M.
    Diabet Med; 2012 Mar 18; 29(3):303-12. PubMed ID: 21951030
    [Abstract] [Full Text] [Related]

  • 26. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.
    J Med Econ; 2013 Mar 18; 16(1):30-40. PubMed ID: 22966753
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of Community Health Workers in controlling diabetes epidemic on the U.S.-Mexico border.
    Ryabov I.
    Public Health; 2014 Jul 18; 128(7):636-42. PubMed ID: 24999158
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial.
    Tao L, Wilson EC, Wareham NJ, Sandbaek A, Rutten GE, Lauritzen T, Khunti K, Davies MJ, Borch-Johnsen K, Griffin SJ, Simmons RK.
    Diabet Med; 2015 Jul 18; 32(7):907-19. PubMed ID: 25661661
    [Abstract] [Full Text] [Related]

  • 35. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative.
    De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, Russo G, Rossi MC, Nicolucci A, Guida P, Di Bartolo P, Pontremoli R, AMD-Annals Study Group.
    Nephrol Dial Transplant; 2015 Sep 18; 30(9):1526-33. PubMed ID: 25883195
    [Abstract] [Full Text] [Related]

  • 36. Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals.
    Viazzi F, Russo GT, Ceriello A, Fioretto P, Giorda C, De Cosmo S, Pontremoli R.
    J Nephrol; 2019 Aug 18; 32(4):517-525. PubMed ID: 30478509
    [Abstract] [Full Text] [Related]

  • 37. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
    Silvestris N, Argentiero A, Beretta GD, Di Bartolo P, Montagnani M, Danesi R, Ferrari P, D'Oronzo S, Gori S, Russo A, Acquati S, Gallo M.
    Crit Rev Oncol Hematol; 2020 Oct 18; 154():103066. PubMed ID: 32853883
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.